Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Murray Hill, New Jersey 07974


The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects undergoing cataract surgery.


Inclusion Criteria: - Unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation in the capsular bag. Exclusion Criteria: - Any additional surgical procedures at the time of the cataract surgery - Refractive surgery in the study eye within the past 2 years - History or presence of noninfectious inflammatory ocular disease (e.g., episcleritis, scleritis, uveitis) in either eye - Intraocular pressure of > 21 mm Hg in either eye - Proliferative or severe nonproliferative diabetic retinopathy in either eye - Neovascular/wet age-related macular degeneration in either eye

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery

Official Title:

A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

A.T. Resolve SARL

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Tomasz Sablinski, MD
Study Director
Auven Therapeutics

Study Dates

Start Date:December 2014
Completion Date:September 2015
Completion Type:Actual
Primary Completion Date:September 2015
Primary Completion Type:Actual
Verification Date:February 2019
Last Changed Date:February 4, 2019
First Received Date:December 23, 2014
First Results Date:January 11, 2019

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Proportion of Subjects Reporting no Ocular Pain
Time Frame:Day 3
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Proportion of Subjects With Clearing of Anterior Inflammation
Time Frame:Day 8
Safety Issues:False
Description:score of zero for the Standardization of Uveitis Nomenclature scale

Study Interventions

Intervention Type:Drug
Description:topical therapy
Arm Name:RX-10045 0.05% nanomicellar solution

Study Arms

Study Arm Type:Experimental
Arm Name:RX-10045 0.05% nanomicellar solution
Description:topical eye drops
Study Arm Type:Experimental
Arm Name:RX-10045 0.1% nanomicellar solution
Description:topical eye drops
Study Arm Type:Placebo Comparator
Arm Name:Vehicle
Description:topical eye drops

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:A.T. Resolve SARL

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.